Trevena Reports Third Quarter 2021 Results
15 nov. 2021 07h00 HE
|
Trevena Inc.
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
11 nov. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
08 nov. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
13 oct. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
30 août 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
25 août 2021 07h00 HE
|
Trevena Inc.
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients Patient enrollment...
Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
10 août 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research
12 juil. 2021 07h00 HE
|
Trevena Inc.
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc....
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical
08 juil. 2021 07h10 HE
|
Trevena Inc.
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China ...